Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.55 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | PI4KA | P42356 | 2/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.32 |
| ▸ | KIT | P10721 | 2/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25035574 | 0.92 | ERN1 (0.52) | ERN1BRAFMTORRORCUSP2 | |
| SCHEMBL25034246 | 0.87 | ERN1 (0.47) | ERN1BRAFMTORRORCUSP2 | |
| SCHEMBL25034136 | 0.87 | ERN1 (0.70) | ERN1BRAFMTORRORCUSP2 | |
| SCHEMBL22200794 | 0.86 | ERN1 (0.43) | ERN1BRAFMTORRORCUSP2 | |
| SCHEMBL25035656 | 0.84 | ERN1 (0.50) | ERN1BRAFMTORRORCUSP2 | |
| SCHEMBL25035324 | 0.84 | ERN1 (0.50) | ERN1BRAFMTORRORCUSP2 | |
| SCHEMBL25034230 | 0.84 | ERN1 (0.48) | ERN1BRAFMTORRORCUSP2 | |
| SCHEMBL25035604 | 0.84 | ERN1 (0.48) | ERN1BRAFMTORRORCUSP2 | |
| SCHEMBL22200482 | 0.84 | ERN1 (0.80) | ERN1BRAF | |
| SCHEMBL22191200 | 0.84 | ERN1 (0.80) | ERN1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | ERN1 3167/4885BRAF 563/4885MTOR 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.